GlassScriptPhysician profile
Lien Turley
NPI 1316420359
$22,166.51
in general payments reported to CMS, 2019-2025
30 companies · $4,881 in 2025
The $4,881 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,141 · 2022: $5,225 · 2023: $6,214 · 2024: $3,706 · 2025: $4,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,789.33 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,044.19 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,898.97 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $2,311.16 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $2,150.01 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,745.56 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Vanda Pharmaceuticals INC. | $1,570.30 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,278.28 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $1,055.13 | 2022-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $1,038.67 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $622.63 | 2021-2025 | Trintellix |
| Lundbeck LLC | $594.57 | 2021-2025 | Rexulti |
| Noven Therapeutics, LLC | $522.31 | 2024-2025 | Xelstrym, Secuado |
| Corium, LLC | $373.08 | 2023-2025 | Azstarys |
| Almatica Pharma LLC | $340.39 | 2022-2025 | Loreev Xr, Teriparatide, Gralise |
| Tris Pharma INC | $269.12 | 2022-2025 | Dyanavel Xr |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $224.92 | 2024-2025 | |
| Neos Therapeutics, LP | $210.45 | 2022-2025 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $202.58 | 2025 | Qelbree |
| Bausch Health US, LLC | $177.14 | 2022-2025 | Aplenzin, Wellbutrin |
| Indivior INC. | $114.40 | 2022-2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $95.53 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $65.05 | 2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $55.42 | 2021-2025 | |
| Sage Therapeutics, LLC | $55.26 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $47.86 | 2021 | |
| Ironshore Pharmaceuticals INC. | $23.63 | 2024 | |
| Alfasigma USA, INC. | $22.70 | 2021 | |
| Neuronetics, INC. | $21.44 | 2023 | Neurostar Tms Therapy System |
| Collegium Pharmaceutical, INC. | $19.03 | 2025 | Jornay Pm |
| Eisai INC. | $16.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lien Turley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.